67074-63-9

Usage

Uses

Used in Pharmaceutical Research:
4-METHYL-3,4-DIHYDROQUINOXALIN-2(1H)-ONE is utilized as a lead compound in pharmaceutical research for its potential to contribute to the development of new drugs. Its biological activities, including antitumor and antimicrobial properties, make it a promising candidate for further exploration and synthesis in the creation of novel therapeutic agents.
Used in Organic Synthesis:
In the field of organic synthesis, 4-METHYL-3,4-DIHYDROQUINOXALIN-2(1H)-ONE serves as an important intermediate or building block for the synthesis of more complex organic molecules. Its unique structure allows it to be a key component in the formation of various organic compounds, contributing to the advancement of chemical research and the development of new materials.
Used in Drug Discovery:
4-METHYL-3,4-DIHYDROQUINOXALIN-2(1H)-ONE is employed as a starting point in drug discovery processes. Its potential as a lead compound is attributed to its demonstrated biological activities, which can be harnessed to develop new pharmaceuticals with specific therapeutic targets, particularly in the areas of oncology and infectious diseases.
Used in Antitumor Applications:
In the oncology sector, 4-METHYL-3,4-DIHYDROQUINOXALIN-2(1H)-ONE is used as a potential antitumor agent. Its biological activity against tumor cells makes it a candidate for further research and development into a therapeutic agent that could be used in the treatment of various types of cancer.
Used in Antimicrobial Applications:
4-METHYL-3,4-DIHYDROQUINOXALIN-2(1H)-ONE is also used as an antimicrobial agent, given its ability to exhibit activity against certain microorganisms. This property is valuable in the development of new antibiotics or antifungal agents to combat drug-resistant infections.

InChI:InChI=1/C9H10N2O/c1-11-6-9(12)10-7-4-2-3-5-8(7)11/h2-5H,6H2,1H3,(H,10,12)

Upstream product

• 2836-03-5 N,N-dimethyl-1,2-phenylenediamine 
• 50-00-0 formaldehyd 
• 59564-59-9 1,2,3,4-tetrahydroquinoxalin-2-one 
• 95-54-5 1,2-diamino-benzene 
• 1049772-54-4 C₉H₁₁BrN₂O*ClH 
• 610-17-3 N,N-dimethyl-2-nitro-benzenamine 
• 714194-84-0 2-chloro-N-(2-(dimethylamino)phenyl)acetamide 
• 80-48-8 methyl p-toluene sulfonate 

Downstream Products

• 120589-83-5 benzyl 3,4-dihydro-4-methyl-2(1H)-quinoxalinone-1-acetate 
• 870072-69-8 2-(4-methyl-3,4-dihydro-2H-quinoxalin-1-yl)phenylamine 
• 870072-68-7 1-methyl-4-(2-nitro-phenyl)-1,2,3,4-tetrahydro-quinoxaline 

Relevant academic research and scientific papers

Heteroaryl amide derivative and use thereof as TGR5 agonist

The invention belongs to the technical field of medicines, and in particular relates to a heteroaryl amide TGR5 agonist compound represented by formula (I) and pharmaceutically acceptable salts, esters, stereoisomers or prodrugs thereof, wherein R1, R2, R

Conformationally constrained ortho- Anilino diaryl ureas: Discovery of 1-(2-(1′-Neopentylspiro[indoline-3,4′-piperidine]-1-yl)phenyl) -3-(4-(trifluoromethoxy)phenyl)urea, a potent, selective, and bioavailable P2Y1 antagonist

Preclinical antithrombotic efficacy and bleeding models have demonstrated that P2Y1 antagonists are efficacious as antiplatelet agents and may offer a safety advantage over P2Y12 antagonists in terms of reduced bleeding liabilities. In this article, we describe the structural modification of the tert-butyl phenoxy portion of lead compound 1 and the subsequent discovery of a novel series of conformationally constrained ortho-anilino diaryl ureas. In particular, spiropiperidine indoline-substituted diaryl ureas are described as potent, orally bioavailable small-molecule P2Y1 antagonists with improved activity in functional assays and improved oral bioavailability in rats. Homology modeling and rat PK/PD studies on benchmark compound 3l will also be presented. Compound 3l was our first P2Y1 antagonist to demonstrate a robust oral antithrombotic effect with mild bleeding liability in the rat thrombosis and hemostasis models.

Practical synthesis of quinoxalinones via palladium-catalyzed intramolecular N-arylations

A practical and highly efficient route to the synthesis of pharmaceutically interesting quinoxalinone scaffolds is reported. The key step involves an intramolecular palladium-catalyzed N-arylation under microwave irradiation. The developed methodology tolerates a variety of bromoanilides to afford a diverse collection of bicyclic and polycyclic quinoxalinones in high yield.

Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions

The present invention provides novel ureas containing N-aryl or N-heteroaryl substituted heterocycles and analogues thereof, which are selective inhibitors of the human P2Y1 receptor. The invention also provides for various pharmaceutical compositions of the same and methods for treating diseases responsive to modulation of P2Y1 receptor activity.

Synthesis of tri- and tetracyclic condensed quinoxalin-2-ones fused across the C-3 - N-4 bond

We have studied the preparation of some fused quinoxalinones by Stevens rearrangement of a spiro-quinoxaline-derived ammonium ylide or by treatment of N-(2,4-dinitrophenyl)-and N-(2-nitrophenyl)imino acids with different reducing agents. We have reinvestigated and clarified some related processes found in the literature starting from imino acids derivatives. Additional reactions of the fused quinoxalinones, as well as the useful dehydrogenation/decarboxylation of some easily available 1-arylindoline-2-carboxylic acids to the corresponding 1-arylindoles, are also reported. Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2003.

Synthesis of quinoxaline derivatives from substituted acetanilides through intramolecular quaternization reactions

The cyclization of 2-dialkylamino-2′-halogeno- and 2-chloro-2′-(dialkylamino)acetanilides to quinoxaline derivatives has been studied in detail. These reactions proceed, respectively, through intramolecular aromatic nucleophilic or aliphatic nucleophilic

Synthesis and aldose reductase inhibitory activity of N-1,N-4-disubstituted 3,4-dihydro-2(1H)-quinoxalinone derivatives

Synthetic routes have been developed for the preparation of 4-acylated, 4-benzenesulfonylated, and 4-methylated 3,4-dihydro-2(1H)-quinoxalinone-1-acetic acids. One example of the corresponding propionic acid has also been made. These compounds have been evaluated for their ability to inhibit bovine lens aldose reductase in vitro. Some members from this series also show weak activity in vivo, inhibiting sorbitol formation in sciatic nerves of streptozotocin-diabetic rats.